CSS
AXDX

Cubist Systematic Strategies’s Accelerate Diagnostics AXDX Stock Holding History

Cubist Systematic Strategies’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,877
Closed -$29K – 4235
2022
Q3 		$29K Buy
+1,877
New +$31.1K ﹤0.01% 4198
2022
Q1 		– Sell
-1,215
Closed -$63K – 3552
2021
Q4 		$63K Sell
1,215
-576
-32% -$32.1K ﹤0.01% 3281
2021
Q3 		$104K Buy
+1,791
New +$117K ﹤0.01% 2734
2021
Q1 		– Sell
-6,389
Closed -$484K – 2824
2020
Q4 		$484K Buy
6,389
+1,077
+20% +$96.4K 0.01% 1784
2020
Q3 		$566K Buy
5,312
+3,028
+133% +$420K 0.01% 1676
2020
Q2 		$346K Buy
2,284
+244
+12% +$24.1K 0.01% 1785
2020
Q1 		$170K Buy
+2,040
New +$287K ﹤0.01% 1790
2019
Q2 		– Sell
-69
Closed -$14K – 2444
2019
Q1 		$14K Buy
+69
New +$12.9K ﹤0.01% 2185

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cubist Systematic Strategies's AXDX Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of Accelerate Diagnostics (AXDX) in Q4 2022, closing a stake of 1,877 shares — an estimated $29K sold.

Cubist Systematic Strategies first reported a position in AXDX in Q1 2019 and held it in 8 quarters. The position peaked at $566K in Q3 2020. 73 funds tracked by Wall St. Rank hold AXDX as of Q4 2022.

  • Cubist Systematic Strategies reported no remaining Accelerate Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,877 Accelerate Diagnostics shares in Q4 2022, an estimated $29K.
  • Cubist Systematic Strategies first reported a position in Accelerate Diagnostics in Q1 2019 and held it in 8 quarters.
  • Cubist Systematic Strategies's Accelerate Diagnostics position peaked at $566K in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.